Sharekhan

#SharekhanResearch retains Buy rating on #Divis (12month PT Rs 4450) #Q1FY23 reslts missed est, encouraging growth… https://t.co/iPsNgGO74a #SharekhanResearch #Divis #Q1FY23

#SharekhanResearch retains Positive view on #CaplinPoint (Upside 20%) #Q1 was a strong quarter; focus to strengthen… https://t.co/WJhyG5RbY9 #SharekhanResearch #CaplinPoint #Q1

#SharekhanResearch #Q1FY23 Pharma Preview, India bizz gwth to be healthy while US bizz to be under pressure; high b… https://t.co/UrsYZaDh73 #SharekhanResearch #Q1FY23

#SharekhanResearch retains Buy on #SanofiIndia(PT Rs9250) #Q1CY22 strng qtr, focus on diabetology, gwth in top prdc… https://t.co/leABFh5zRR #SharekhanResearch #SanofiIndia #Q1CY22

#SharekhanResearch #Q1FY22 Pharma Review; healthy show, performance driven by strong growth in India bizz while hea… https://t.co/uMNA3Rmidz #SharekhanResearch #Q1FY22

#SharekhanResearch retains Buy rating on #Lupin (PT Rs1400) #Q1FY22 results marginally miss estimates; India bizz t… https://t.co/POnpFWZ49q #SharekhanResearch #Lupin #Q1FY22

#SharekhanResearch retains Buy rating on #Cadila (PT Rs 720) reports healthy performance for #Q1FY22; Strong growth… https://t.co/gtZyYOCd4n #SharekhanResearch #Cadila #Q1FY22

#SharekhanResearch retains Buy rating on #Cipla (PT Rs 1150) #Q1FY22 strng qtr, results beat estimates; strengtheni… https://t.co/08yhJtou3s #SharekhanResearch #Cipla #Q1FY22

#SharekhanResearch retain Buy on Transport Corp of India with unchanged PT of Rs541, #Q1FY22 beat led by higher OPM… https://t.co/ps878v5lLy #SharekhanResearch #Q1FY22